LIXTE BIOTECHNOLOGY HOLDINGS, INC. Uncategorized Contracts & Agreements
18 Contracts & Agreements
- Clinical Trial Agreement dated as of June 10, 2024 between the Company and the Netherlands Cancer Institute (Filed With SEC on June 14, 2024)
- Amendment to Contract between Lixte Biotechnology Holdings, Inc. and MRI Global effective April 17, 2022 (Filed With SEC on May 10, 2023)
- Insider Trading Policy (Filed With SEC on March 29, 2023)
- Form of Underwriter Agreement (Filed With SEC on November 16, 2020)
- Form of Underwriter Agreement (Filed With SEC on October 13, 2020)
- Description of the Registrants Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934 (Filed With SEC on March 25, 2020)
- Clinical Trial Research Agreement1 (Filed With SEC on August 6, 2019)
- Clinical Trial Research Agreement1 (Filed With SEC on August 23, 2018)
- SECURITIESPURCHASE AGREEMENT (Filed With SEC on April 10, 2017)
- EXCLUSIVELICENSE AGREEMENT (Filed With SEC on December 30, 2015)
- ADVISORYAGREEMENT (Filed With SEC on November 10, 2015)
- STOCKOPTION AGREEMENT (Filed With SEC on November 10, 2015)
- CollaborationAgreement between the Company and BioPharmaWorks LLC (Filed With SEC on September 18, 2015)
- SCIENTIFICADVISORY BOARD AGREEMENT (Filed With SEC on March 21, 2014)
- CONSULTINGAGREEMENT (Filed With SEC on November 12, 2009)
- AMENDMENT (Filed With SEC on May 14, 2008)
- EXHIBIT 10.1 (Filed With SEC on February 9, 2007)
- EXHIBIT 2.1 (Filed With SEC on July 7, 2006)
